Related Experiment Video
Updated: Jan 11, 2026

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
Cefiderocol and Moxifloxacin Have Additive and Synergistic Activity Against Pseudomonas aeruginosa Including an
Eric G Romanowski1, Brennan M Schilling2, Emily K Young1
1Charles T. Campbell Laboratory, Department of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States.
Purpose:
The 2023 outbreak of Pseudomonas aeruginosa keratitis linked to contaminated artificial tears highlighted the need for new treatments targeting ocular infections caused by multi-drug-resistant and extensively drug-resistant bacteria. This study evaluated the in vitro efficacy and potential synergy of cefiderocol and moxifloxacin against P. aeruginosa keratitis isolates. The influence of quorum-sensing defects on antibiotic efficacy was also assessed because of the increase in lasR mutant keratitis isolates. Ceftazidime, which lacks the "Trojan Horse" iron-binding-mediated bacterial entry mechanism of cefiderocol, served as a comparator.
Methods:
Time-kill and epsilometer (E-test) assays were used to determine minimum inhibitory concentrations and drug interactions. Fractional inhibitory concentration indices were calculated to characterize drug interactions as antagonistic, indifferent, additive, or synergistic. Quorum-sensing defective strains were identified by a characteristic colony sheen phenotype associated with LasR system defects.
Results:
Time-kill studies demonstrated consistent synergistic interactions between cefiderocol and moxifloxacin against seven out of seven tested P. aeruginosa keratitis isolates, including one from the 2023 outbreak. E-test-based assays showed additive or synergistic activity against 79% of isolates, although this dropped to 60% among suspected quorum-sensing defective strains. In contrast, the ceftazidime and moxifloxacin combination was less effective, particularly sheen-positive strains. The cefiderocol-moxifloxacin combination showed indifferent effects against Serratia marcescens and Staphylococcus aureus, with each antibiotic retaining individual activity.
Conclusions:
Cefiderocol and moxifloxacin exhibited synergy against most tested P. aeruginosa keratitis isolates in vitro, including those with suspected quorum-sensing defects. These findings support further investigation of this combination for treating highly drug-resistant ocular infections.
Insights
Cefiderocol and moxifloxacin show synergy against drug-resistant Pseudomonas aeruginosa keratitis. This combination offers a promising new treatment for challenging ocular infections caused by resistant bacteria.
Area of Science:
- Ophthalmology
- Infectious Diseases
- Microbiology
Background:
- The 2023 Pseudomonas aeruginosa keratitis outbreak highlighted the urgent need for novel treatments against multi-drug-resistant (MDR) and extensively drug-resistant (XDR) bacteria.
- Increased prevalence of lasR mutant keratitis isolates necessitates understanding quorum-sensing defects' impact on antibiotic efficacy.
Purpose of the Study:
- To evaluate the in vitro efficacy and synergistic potential of cefiderocol and moxifloxacin against P. aeruginosa keratitis isolates.
- To assess the influence of quorum-sensing defects on the efficacy of this antibiotic combination.
- To compare cefiderocol-moxifloxacin synergy with ceftazidime-moxifloxacin, using ceftazidime as a comparator lacking cefiderocol's iron-binding entry mechanism.
Main Methods:
- Time-kill assays and epsilometer (E-test) were employed to determine minimum inhibitory concentrations (MICs) and drug interactions.
- Fractional inhibitory concentration indices (FICI) were calculated to classify interactions as antagonistic, indifferent, additive, or synergistic.
- Quorum-sensing defective strains were identified via a characteristic colony sheen phenotype linked to LasR system defects.
Main Results:
- Consistent synergistic interactions between cefiderocol and moxifloxacin were observed in time-kill studies against all seven tested P. aeruginosa keratitis isolates, including one from the 2023 outbreak.
- E-test assays revealed additive or synergistic activity in 79% of isolates, decreasing to 60% in suspected quorum-sensing defective strains.
- The ceftazidime-moxifloxacin combination demonstrated reduced efficacy, especially against sheen-positive strains. Cefiderocol-moxifloxacin showed indifferent effects against Serratia marcescens and Staphylococcus aureus.
Conclusions:
- Cefiderocol and moxifloxacin exhibit significant in vitro synergy against the majority of tested P. aeruginosa keratitis isolates, even those with quorum-sensing defects.
- This combination warrants further investigation as a potential therapeutic strategy for managing highly drug-resistant ocular infections.
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Antimicrobial Effectiveness
Antibiotic Selection
Gene Regulation in Microbial Communities: Quorum Sensing

